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Wednesday, March 4 
10:30 - 12:00  Studio 2015 
SY 1  
The power of MRI in breast diagnostics 
and therapy  
Moderator:  
S.H. Heywang-Köbrunner; Munich/DE  
Future trends in breast MRI: TWIST-VIBE for breast cancer staging in 2 
min  
R.M. Mann; Nijmegen/NL  
Breast MRI has obtained a solid position in the radiological evaluation of the 
breast. Its 3-dimensional nature allows for an easier understanding of the 
location and extension of abnormalities within the breasts. The large amount of 
information that can be obtained using different scan sequences allows for a 
much better understanding of the biological processes taking place within 
breast abnormalities. The criticism which has accompanied breast MRI is 
usually fed by the relatively high costs of the procedure. In screening for breast 
cancer, costs are the sole issue that have prevented MRI screening programs 
to extend beyond the population with hereditary breast cancer. This can be 
partly solved by differentiating the women that currently undergo breast MRI by 
indication, i.e. a women with known breast cancer for whom the possible 
success of a chemotherapeutic regimen is questioned should undergo a 
completely different MRI scan than a women being screened for a moderately 
increased risk. This differentiation has been hypothesised upon, but has not 
really been implemented in clinical practice. Nevertheless, new protocols have 
been described that perform a complete evaluation of the breasts much 
quicker than conventional multiparametric MRI. TWIST-VIBE for example 
documents the inflow of contrast and provides morphologic information as well 
as information on tissue composition whilst it can be obtained in less than 2 
minutes. The question is subsequently how to use this to our advantage, rather 
than adding it again to the already lengthy breast MRI protocol. 
MR for operation planning  
C.K. Kuhl; Aachen/DE  
Breast MRI: insights from recent clinical trials  
J. Barkhausen; Lübeck/DE  
More than 30 years ago MRI emerged as a new technique in clinical breast 
imaging and over the last three decades numerous clinical studies have shown 
excellent results for the detection and characterisation of breast lesions. 
However, despite this tremendous gain in knowledge breast MRI still has its 
share of controversies including appropriate indications for screening and 
appropriate indications for preoperative breast MRI. In this lecture, the results 
of the most recent clinical trials addressing these topics will be presented in a 
comprehensive manner and the impact of these studies on daily clinical routine 
will be discussed. Additionally, there are several new indications for breast MRI 
bearing in mind that breast cancer subsumes different diseases with varying 
histologic subtypes, clinical presentations and treatment responses. Therefore, 
several studies aim to investigate the associations between MR imaging 
features and breast cancer subtypes as well as treatment responses. The 
second part of the lecture will give an overview on the recent efforts to 
characterise cancer subtypes and to support individualised tumour treatment 
based on quantitative parameters extracted manually or semiautomatically 
from multiparametric breast MRI data sets. 
Learning Objectives: 
1. To gain knowledge on the results of the most recent breast MRI trials. 
2. To discuss the impact of the results on the management of breast lesions. 
3. To learn about future developments and applications. 
Positive long-term results after implementing intensive breast MRI use in 
an area population  
J. Camps Herrero; Valencia/ES  
Breast MRI has asserted itself as the most sensitive breast imaging modality 
for the diagnosis of breast cancer. Yet, two randomised controlled trials 
(COMICE and MONET) have failed to demonstrate that it can improve re-
excision rates as a staging tool in patients with breast cancer. A recent 
randomised clinical trial (POMB), albeit with a large proportion of mastectomies 
in the MRI arm, has proven that breast MRI does reduce significantly the rate 
of re-interventions. As it stands, breast MRI is not included in the guidelines as 
a staging tool. In the geographical Spanish area of La Ribera we have been 
using breast MRI intensively since 2002, not only as a staging procedure, but 
also in patients treated with neoadjuvant chemotherapy, patients with a 
personal history of breast cancer, hereditary breast cancer risk, high-risk 
lesions, suspicious nipple discharge, microcalcifications, BIRADS 3-5 or 
distortions and in general as a problem-solving tool. The data we herein 
present will show that not only staging MRI can reduce the re-excision rates in 
patients with a diagnosis of breast cancer, but is also an excellent modality 
that, due to its high negative predictive value, can save additional biopsies and 
surgery. The future of radiology belongs to the development of imaging 
biomarkers and breast MRI is an excellent image biomarker of angiogenesis 
and cellular density that provides us with a static and dynamic complete image 
of a tumour in all its heterogeneity and complexity. 
12:15 - 13:45 Studio 2015 
SY 2  
Multimodality lunch symposium: planning 
and control of breast cancer therapy  
Moderator:  
C. Van Ongeval; Leuven/BE  
Introduction  
C. Van Ongeval; Leuven/BE  
Strain imaging ultrasound technology (virtual touch IQ)  
M. Golatta; Heidelberg/DE  
Strain imaging ultrasound technology as Virtual Touch IQ (VTIQ) is a new 
method being used in breast ultrasound. Strain imaging in general has multiple 
fields of application in assessing the stiffness of tissue. Reports are found on 
the assessment of liver, thyroid, kidney, prostate and breast tissue. Concerning 
breast ultrasound strain imaging is mainly used in the assessment of lesions. 
Based on the first study results, elastography is mentioned in the 5th BIRADS® 
catalogue and has been added as a further assessment method. There are 
various methods of elastography allowing a qualitative assessment on the one 
hand freehand elastography or quantitative assessment on the other hand 
ShearWave Elastography, e.g. VTIQ of either lesions or breast tissue. 
Elastography is a non-invasive radiationless diagnostic method which allows 
further assessment of breast lesions. Various studies have been able to show 
an increase of the diagnostic specificity without loss of sensitivity when 
combining the standard ultrasound BIRADS® classification with elastography. 
The improvement of the specificity will help to eliminate unnecessary breast 
biopsies in the future. 
Value of digital breast tomosynthesis for preoperative local staging of 
breast cancer  
L.J. Pina Insausti; Pamplona/ES  
Digital Breast Tomosynthesis (DBT) is used as an additional technique after 
Digital Mammography (DM) in two main scenarios: first, to increase the 
detection of malignant lesions after normal mammography, especially in dense 
breasts; second, DBT can be used as a problem-solving technique when a 
lesion is detected on DM. We hypothesised that preoperative DBT could help 
to detect additional cancers not detected on DM, changing the initial surgical 
treatment. The aim of this study is to assess the role of DBT in the 
preoperative assessment of patients with recently diagnosed breast cancer. 
For this purpose, we conducted a retrospective lesion-based study of 91 
patients with histologically proven breast cancer. All of them underwent DM, 
DBT and MRI. An expert radiologist who was blinded for the final diagnoses 
reviewed both DM and DM in conjunction with DBT. The gold standard was 
surgery (after MRI and second-look US information). The PEPI software was 
used to calculate the sensitivity and the statistical significance. 122 malignant 
lesions in 91 patients were our gold standard. DM detected 71 cancers and 
DBT discovered 23 additional cancers (+32.4%). The sensitivity of DM was 
58.2%, the sensitivity of DM+DBT was 77.0% and the difference was 
statistically significant (p<0.05). The initial surgical treatment changed in 22 
patients (24.1%), from conservative treatment to mastectomy in 5 patients 
(5.5%) and from lumpectomy to wider excision (but conservative) in the 
remaining 17 patients (18.6%). DBT increases the sensitivity of DM, detecting 
up to 32.4% additional cancers and changing the initial surgical treatment in 
24.1% of patients. 
Learning Objectives: 
1. To study the role of preoperative DBT in breast cancer patients. 
2. To show the changes induced by DBT in the initial surgical treatment. 
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Whole body MRI: changing the management paradigm for metastatic 
bone disease  
A.R. Padhani; London/UK 
Metastatic breast cancer to bone has detrimental impact on patients’ quality 
and quantity of life. Since treatments are palliate, the control of bony metastatic 
disease is vital in maintaining patient health for as long as possible. The 
treatment of advanced breast cancer with bony metastases has significant 
health economic implications. To effectively manage patients it is essential to 
have consistent, reproducible and validated methods of assessing response to 
therapy. A review of biology of bone metastases and measures of response 
assessment including clinical assessment, tumour markers and imaging 
techniques (BS, CT, PET, MRI and whole body diffusion-weighted MRI (WB 
DW-MRI)) will be presented. The current standard of care of BS and CT has 
significant limitations and is not routinely recommended for response 
assessment in the bones. Morphologic response criteria on MRI have a 
number of problems including (1) arrested resolution of abnormalities despite 
effective therapy, (2) evaluating disease activity on scarred background is 
problematic, (3) T1-pseudoprogression due to bone oedema, (4) the sclerotic 
progression phenomenon, and (5) mixed response patterns. Therapy 
assessments on WB-DWI are made by observing changes in the volume and 
symmetry of signal intensity abnormalities on high b-value images together 
with changes in ADC values and distinct patterns are recognised. Cross-
correlating DWI with morphological appearances remains important. WB- MRI 
has the potential to address the unmet need for assessing metastatic breast 
cancer. 
Learning Objectives: 
1. To know the indications for imaging metastatic breast cancer patients. 
2. To learn how to perform whole body MRI in a time efficient manner. 
3. To learn about the benefits of whole body MRI in addressing limitations of 
current imaging for bone metastatic detection and response assessment. 
4. To understand the how the biology of metastatic bone disease affects 
imaging findings. 
5. To be able to enumerate patient care indications for whole body MRI in 
metastatic disease. 
Integration of molecular diagnostics in breast imaging  
P.A. Fasching, R. Schulz-Wendtland; Erlangen/DE  
Modern breast imaging methods have opened the way to personalised 
medicine in radiology similar to the treatment of breast cancer patients. In 
treatment and also in prevention, personalised medicine is either already a part 
of standard care or is about to be implemented in daily practice. Experience 
with molecular markers and predictive tests for breast cancer risk and breast 
cancer prognosis is the ideal basis for integrating molecular diagnostics into 
imaging methods. This can happen either by integrating the visualisation of 
certain molecules into the imaging method or by utilising established molecular 
markers for established diagnostic procedures like mammography screening or 
breast diagnostic procedures in daily routine. Here, we report on the current 
knowledge, how to utilise validated molecular markers together with breast 
imaging methods. Breast cancer risk prediction has evolved immensely over 
the last 10 years, establishing mammographic density and low penetrance 
genetic markers along with already known high penetrance markers. So far 
about 100 genetic variants, which are common in a population, have been 
validated, some of which interact with characteristics of the tumour or 
mammographic density, implying a relevant impact on diagnostics by the 
means of sensitivity, specificity, and predictive values. The development of 
imaging methods in fusion machines enables the personalised combination of 
several imaging methods. Whilst additional imaging methods in a diagnostic 
unit of symptomatic patients seems already feasible, the maintenance of a high 
specificity is the main goal in the screening setting. Molecular markers will help 



















14:00 - 15:30 Studio 2015 
SY 3 
Advantages of 3D and hybrid technologies 
in mammography  
Moderator:  
R.M. Mann; Nijmegen/NL  
Routine use of digital breast tomosynthesis (DBT) for the assessment of 
screen-detected cases  
S.H. Heywang-Köbrunner; Munich/DE  
Due to the detection of a high percentage of early lesions screening 
assessment proves a demanding task. Since January 2012, after finishing a 
comparative study, and based on the allowance by radiation protection, DBT 
has been applied for routine assessment of screen-detected abnormalities. 
Based on approximately 1000 consecutive assessment cases we analysed the 
use and reliability of DBT in routine assessment and the remaining need for 
additional views. Examples of present limitations and of the special advantages 
of DBT are shown. DBT proves most valuable for evaluation of abnormalities 
seen on one view only, since it helps targeting further work-up (ultrasound, 
further views or percutaneous biopsy) in the correct location. Furthermore, it 
usually allows excellent distinction of superimposition from a true mass, an 
architectural distortion or an asymmetry. It may be helpful identifying the fatty 
hilum in a suspected lymph node and assessing a lesion partly covered by 
dense tissue. With the present technique assessment of margin sharpness of 
masses and of morphology and distribution of microcalcifications is still 
superior on magnification views. Dosages for standard assessment with versus 
without DBT will be discussed. The potential of correctly used DBT concerns 
the reduced need for supplementary views, reduced recommendations for 
short-term follow-up and stereotactic breast biopsy. 
Learning Objectives: 
1. To understand possibilities and limitations of using DBT for screening 
assessment. 
2. To learn about the additional information that may be expected from DBT 
and possible pitfalls depending on the indication. 
3. To consider potentials of DBT for decreasing radiation dosage associated 
with screening assessment. 
Requirements for digital reading in breast care: a report from the practice  
K. Ridder; Dortmund/DE  
Reading in Breast Care is more than ever before a matter of multimodality 
reading, with large data volumes and high throughput, especially in screening. 
This means high performance requirements for both the radiologist and the 
workplace. Dealing with different reading workplaces for different modalities 
with different user interfaces results in cumbersome procedures, difficult image 
comparisons and inefficient workflows. This leads to time-consuming reading 
and in the worst case to a loss of information. Additionally, new technologies 
like digital breast tomosynthesis require new methods for fast and efficient 
reading. An approach to address the challenges of today´s multimodality 
reading in mammography is accessing and handling different image types on 
one and the same workplace. An open and scalable client-server application 
for breast care includes MRI, ultrasound, mammography and tomosynthesis 
reading with a common user interface and comprehensive tools across all 
modalities. Customisable layouts and configurable workflows allow for 
standardised reading and comparison with priors, especially in screening. 
Integrated BIRADs protocols and detailed CAD information enable a large 
number of examinations with a short reading time. Simultaneous reading 
requirements from different locations such as a tumour board office can be 
better addressed with a server-client approach. In my presentation, I will use 
the example of syngo.via Breast Care to discuss what a digital image reading 
system has to perform and will illustrate it with clinical examples from the daily 
routine. 
Learning Objectives: 
1. To understand the challenges of multimodality breast diagnostics. 
2. To learn about approaches to optimize mammo reading and diagnostics. 
3. To discuss requirements for future developments of imaging systems. 
Experiences with a breast ultrasound - tomosynthesis hybrid  
M. Golatta; Heidelberg/DE  
The introduction of digital mammography throughout the last years has had a 
large impact on breast imaging. The digital imaging allows editing of the data 
and through that analysing processed images. Digital breast tomosynthesis is 
one method that has been developed. Multiple low-dose images are obtained 
from predefined angles under compression and are digitally edited and 
reconstructed as a 3D-image of a breast. The reconstructed 3D-image 
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overcomes the weakness of standard mammography and enables to reduce 
false-positive findings as results of overlapping tissue. On the other hand, it 
enables to reduce the false-negative findings in women with dense breast 
tissue. Dense breast tissue is a known limitation to the sensitivity of standard 
mammography. Studies have shown that combing ultrasound with 
mammography in screening settings can significantly improve the rate of found 
lesions. First approaches of combing standard mammography with automated 
ultrasound in one device were reported 15 years ago. The benefits in breast 
cancer imaging using automated ultrasound and digital 
mammography/tomosynthesis either in two separate devices or as a combined 
proto-type have been assessed to some degree. Proto-types have been 
developed with the attempt of simultaneously obtaining tomosynthesis and 
automated breast volume scanning by ultrasound to improve screening for 
breast cancer by comparing two 3D-images obtained under the same 
compression. With this study we are planning to present first results with a 
proto-type system combining tomosynthesis with ABVS to assess the benefits 
of this combination. 
16:00 - 17:00 Studio 2015 
SY 4  
The dense breast - a challenge: 
multimodality breast image reading and 
discussion of clinical cases  
Moderator:  
C. Van Ongeval; Leuven/BE  
MRI perspective  
E. Wenkel; Erlangen/DE  
The expression “dense breast” is determined on mammography. The 
mammographic breast density is reflected by the amount of fibroglandular 
tissue of the breast. The higher the percentage of fibroglandular tissue the less 
sensitive becomes the mammogram for detecting breast cancer because 
cancer can be masked by dense tissue. As breast density is an established 
predictor of breast cancer risk additional imaging techniques like ultrasound, 
tomosynthesis and MRI are discussed to increase sensitivity. Breast density is 
dependent on the age and the hormonal status of the women. 
Mammographically dense breast tissue is not reflected in the same way in 
breast MRI. Difficult interpretation of breast MRI due to hormonally stimulated 
breast tissue does not necessarily correspond to mammographically dense 
breasts and vice versa. Mammographic breast density does not correlate with 
the background ground enhancement of normal breast tissue on MRI. Studies 
showed that MRI detects more breast cancers compared to mammography 
especially in younger women with hereditary breast cancer and dense breast 
tissue.  
Learning Objectives: 
1. To learn the indication of MRI with respect to mammographic breast density. 
2. To learn the presentation of normal breast tissue in mammographically 
dense breasts compared to MRI. 
3. To show the differences of dense breasts in mammography and MRI. 
Tomo/mammo perspective  
M. Bernathova; Vienna/AT  
Up to 30% of cancers in screening programs are not detected by the standard 
digital mammography (DM). In 52-76% of all cases, cancers are missed in very 
dense breast tissue. Due to the superimposition of different anatomical 
patterns, a lesion might not become visible because the tissue above or 
underneath may mask it. Furthermore, the superimposition of normal structures 
in the breast may mimic a lesion. Digital Breast Tomosynthesis (DBT) as a 
three-dimensional radiographic technique is expected to decrease the 
superimposition effect by reducing tissue overlap and making lesions more 
conspicuous. DBT is proven to detect smaller cancers earlier, thus increasing 
the detection rate significantly, as well as reducing the number of false-positive 
diagnoses and recall rates. For BIRADS 3 lesions, DBT can result in a better 
classification of the abnormality; for BIRADS 5 lesions, a better definition of the 
tumour size and multi-focality can be realised. The use of DBT may eliminate 
the spot compressions, magnification views and further projections in the 
diagnostic set-up. We will discuss clinical cases where DBT improved the 
detection of additional cancers not seen on DM. Furthermore we will evaluate 
tomosynthesis as a complementary technique for the evaluation of lesions 
detected on DM, especially in breast density ACR Grade 2-4. We will also 
demonstrate why some lesions can be hidden in very dense breasts (ACR 
pattern 4) even for DBT. And last but not least, it has to be discussed whether 
in some cases additional breast ultrasound or breast MRI can be avoided.  
Learning Objectives: 
1. To learn about advantages and disadvantages of the different imaging 
methods in the imaging of dense breast. 
2. To show complementary DBT in the diagnosis of breast lesions. 
3. To understand the impact of DBT on the diagnostic work out. 
12:30 - 13:30 Room G 
SY 5  
EURATOM: what is the return on 
compliance?  
Moderator:  
J.E. Wildberger; Maastricht/NL  
Quality improvements: reducing variation and dose through dose 
management tools  
S.T. Schindera; Basle/CH  
Efficiency improvements: utilisation tracking through dose management 
tools  
M. Das; Maastricht/NL  
12:30 - 13:30 Room M 
SY 6  
Present and future of UltraFast™ 
ultrasound imaging: the revolution moves 
on  
Moderator:  
C.F. Dietrich; Bad Mergentheim/DE  
Integration of ShearWave™ elastography to conventional ultrasound 
imaging in light of the EFSUMB recommendations 
C.F. Dietrich; Bad Mergentheim/DE  
The benefits of using UltraFast™ ultrasound imaging in paediatric 
patients 
S. Franchi-Abella; Le Kremlin-Bicêtre/FR 
ShearWave™ elastography is accurate in identifying prostate cancer 
G. Salomon; Hamburg/DE 
Future applications of UltraFast™ ultrasound imaging: towards 
functional ultrasound 
M. Tanter; Paris/FR  
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Thursday, March 5 
12:30 - 13:30 Room F2 
SY 7  
Innovative choices in cardiovascular 
imaging  
Moderator:  
J.E. Wildberger; Maastricht/NL  
Great vessels  
J.E. Wildberger; Maastricht/NL  
Peripherals  
T. Leiner; Utrecht/NL  
Heart 
M. Gutberlet; Leipzig/DE  
12:30 - 13:30 Room E1 
SY 8  
Evolving needs in CT imaging: a patient-
centred approach  
Moderator:  
L. Bonomo; Rome/IT  
Advanced CT technology: how to minimise patient dose 
T. Henzler; Mannheim/DE 
Standardisation of scanning protocols and patient diversity: oil and 
water? 
M. Prokop; Nijmegen/NL 
Tailoring CT scans to individual patients: design and validation 
A. Vanzulli; Segrate/IT 
12:30 - 13:30 Room K 
SY 9  
Advances of MR and PET/MR in oncology: 
imagine what MR can be  
Moderator:  
L.W. Turnbull; Hull/UK 
The vision of GE of MRI in oncology  
I. Panagiotelis; Waukesha, WI/US  
New improvements in abdominal and pelvic oncologic MRI  
M. Zins; Paris/FR  
Technical and diagnostic experiences in simultaneous TOF-PET/MRI  
P. Veit-Haibach; Zurich/CH  
12:30 - 13:30 Room M 
SY 10  
Leading with MAGNETOM  
Programme not available by date of publication  
 
12:30 - 13:30 Studio 2015 
SY 11  
Driving innovations in ultrasound  
Moderator:  
A. Nilsson; Uppsala/SE   
Improved workflow by using CEUS and image fusion in detection, 
treatment and follow up of liver lesions  
D.-A. Clevert; Munich/DE  
Acoustic Radiation Force Impulse (ARFI) ultrasound and its clinical 
advantages in the liver and pancreas  
M. D'Onofrio; Verona/IT  
The clinical benefits of strain imaging in the breast ultrasound  
C.S. Balleyguier; Villejuif/FR  
12:30 - 13:30 Room G 
SY 12  
Better outcomes from detection to 
treatment  
Moderator:  
C. Roy; Strasbourg/FR   
Advanced ultrasound applications for multidisciplinary use  
T. Fischer; Berlin/DE  
Elastography: improved detection and characterisation  
V. Cantisani; Rome/IT  
Advancements in ultrasound guided biopsy and treatment  
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Friday, March 6 
12:30 - 13:30 Room F2 
SY 13  
Synergies in CT for better patient care  
Moderator:  
M. Lell; Erlangen/DE 
Programme not available by date of publication  
12:30 - 13:30 Room E1 
SY 14  
Moderator:  
L. Martí-Bonmatí; Valencia/ES 
Diagnosis and early detection of pancreatic cancer: current and future 
perspectives 
R. Manfredi; Verona/IT 
MRI in prostate cancer management: an evolving role 
A. Oto; Chicago, IL/US 
Breast cancer screening: who, when and how 
C.K. Kuhl; Aachen/DE 
12:30 - 13:30 Room K 
SY 15  
Breast imaging innovation for better 
patient care  
Moderator:  
L. Katz; Buc/FR  
Breast tomosynthesis experience after 40,000+ examinations  
L. Levy; Paris/FR  
CESM: from initial research to daily clinical routine  
M. Lobbes; Maastricht/NL  
Breast MR: when, why and how  
L.W. Turnbull; Hull/UK  
12:30 - 13:30 Room G  
SY 16  
Guidelines and practice in diagnostic and 
interventional radiology: follow the lines!  
Moderator:  
T.C. Lauenstein; Essen/DE  
Assessment of high-grade glioma with RANO-criteria: can advanced MRI 
imaging techniques help?  
A. Radbruch; Heidelberg/DE  
The radiological assessment of high-grade glioma with magnetic resonance 
imaging is traditionally based on contrast-enhanced T1-weighted images. 
Limitation of this approach is that contrast-enhanced T1-weighted images 
visualise exclusively contrast agent extravasation that is caused by a disruption 
of the blood-brain barrier. According to the Radiology Assessment of Neuro-
Oncology (RANO) criteria that were introduced in 2010, also T2-weighted 
images have to be taken into account to identify infiltrative tumour progression. 
However, RANO criteria are supposed to be working in progress and important 
questions such as the identification of pseudoprogression and pseudoresponse 
remain unsolved. The reliable assessment of these radiological phenomena is 
not only crucial for the individual diagnosis but also for the correct assessment 
in clinical studies. This lecture will highlight the potential role of advanced 
imaging techniques to solve the remaining challenges in neuro-oncologic 
response assessment.  
Best practice in MDCT: how to optimise the radiation reduction and 
iodine use?  
D. Caramella; Pisa/IT  
New technological developments and regulatory constraints reshape the 
routine MDCT practice. In the last decades there has been a significant growth 
of the number of radiological examinations, resulting in an increase of radiation 
dose per capita. Multidetector computed tomography (MDCT) nowadays 
makes the largest contribution amongst X-ray imaging techniques to the 
collective dose of a population. Data from literature indicate that multiple 
imaging procedures are frequently performed, with patients receiving CT scans 
corresponding to an effective cumulative dose of tens of mSv. For this reason, 
it is important to reduce the radiation dose given to patients in every MDCT 
examination without impairing its diagnostic quality, following the strict 
guidelines contained in the new European Directive 2013/59/EURATOM of 5 
December 2013, that gives challenging targets to all stakeholders in terms of 
justification, optimisation and patient information. Recently, iterative 
reconstruction has introduced relevant changes in the practice of MDCT. In 
comparison with the conventional filtered back projection techniques, using 
iterative reconstruction the number of projection views can be significantly 
reduced without sacrificing image quality. Therefore, iterative reconstruction 
algorithms have significant potential to reduce radiation dose in MDCT. These 
technological advancements have also the advantage of allowing optimisation 
of the use of iodinated contrast medium, permitting to obtain better 
enhancement with lower doses, provided that best practices are in use and are 
systematically checked.  
Barcelona-clinic liver cancer guidelines: cTACE positioning within the 
guidelines  
T.C. Lauenstein; Essen/DE  
The incidence of hepatocellular carcinoma (HCC) is increasing worldwide 
during the last decades. Diagnosis and therapy of HCC are based on an 
interdisciplinary approach, where hepatologists, oncologists, surgeons and 
radiologists are involved. Thus, it is important to rely on a general algorithm for 
the treatment of HCC depending on the tumour load and the severity of 
underlying liver disease. The Barcelona Clinic Liver Cancer (BCLC) staging 
system distinguishes five stages with progressively worse prognosis and has 
been validated by several studies. In patients who are not eligible for curative 
resection or liver transplantation but still have disease confined to the liver, 
locoregional therapies play an important role in reducing tumour burden, 
providing palliation of symptoms and improving survival. Transarterial 
chemoembolisation (TACE) represents the standard of care for intermediate 
stage BCLC (B). Furthermore, TACE is used as a bridging and down-staging 
therapy option. Different aspects of TACE within the confines of the BCLC are 
discussed in this presentation. First and foremost, the technique of TACE as 
well as data of clinical outcome will be highlighted. Advantages and 
disadvantages compared to other treatment options, and also the combination 
with different therapeutic approaches, will be described. Eventually, prognostic 
factors for therapy response including liver function and tumour load are 
discussed.  
12:30 - 13:30 Room N  
SY 18  
First time right imaging with Philips MRI  
Moderator:  
E. Jean; Eindhoven/NL  
Introduction 
E. Jean; Eindhoven/NL  
Fast and robust neuro imaging with Ingenia 1.5T 
J. Savatovsky; Paris/FR 
Advanced MRI and visualisation in oncology  
E.M. Pedersen; Aarhus/DK 
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12:30 - 13:30 Room M 
SY 19  
New premium technology of Samsung  
Moderator:  
J. Sunwoo; Seoul/KR  
Introduction of Samsung technology  
J. Sunwoo; Seoul/KR  
Clinical implications of S-Fusion  
M.W. Lee; Seoul/KR  
Clinical values of RS80A ultrasound  
N.N. 
Questions and answers  
12:30 - 13:30 Room C 
SY 20  
New detector technology improves patient 
safety  
Moderator:  
A. de Roos; Leiden/NL  
Safer imaging – clearer outcomes  
J. Hall; Otawara/JP  
New detector technology in clinical practice  
R. Bull; Bournemouth/UK  
Widening the scope of clinical CT applications  
M. Prokop; Nijmegen/NL 
14:00 - 15:30 Room M 
Cardiac  
SY 21  
Multimodal approaches to the perfusion 
and diffusion assessment: expanding 
horizons for medical imaging!  
Moderator:  
I.N. Pronin; Moscow/RU  
Cardiac CT and cardiac GSI in assessment of myocardial scars  
V.E. Sinitsyn; Moscow/RU  
Nuclear and hybrid imaging in assessment of myocardial perfusion: state 
of the art  
K.V. Zavadovskiy; Tomsk/RU  
CT GSI and MRI in assessment of pulmonary perfusion in patients with 
chronic thromboembolic disease  
E.A. Mershina; Moscow/RU  
Perfusion in PET  
D.V. Ryzhkova; Moscow/RU  
Arterial Spin Labeling (ASL): new horizons in brain perfusion assessment  




14:00 - 15:30 Room C 
SY 22  
Screening with breast tomosynthesis: an 
emerging reality  
Moderator:  
P. Skaane; Oslo/NO  
The American experience  
S.M. Friedewald; Chicago, IL/US  
The Spanish experience  
M. Álvarez-Benito; Córdoba/ES  
The Italian experience  
D. Bernardi; Trento/IT  
The Norwegian experience  
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Saturday, March 7 
12:30 - 13:30 Room M 
SY 23  
Contrast-enhanced ultrasound in the 
imaging of patients at risk of developing 
malignant lesions  
Moderator:  
C. Stroszczynski; Regensburg/DE  
The role of CEUS in the detection and diagnosis of liver metastases  
M.C. Beermann; Stockholm/SE  
Surveillance of patients with liver cirrhosis: is there still a role for CEUS?  
V. Cantisani; Rome/IT  
Quantification on DCEUS: new trends and developments  
F. Tranquart; Geneva/CH  
12:30 - 13:30 Room C 
SY 24  
CT and contrast media innovations: a 
patient-centric approach  
Moderator:  
N.N.  
Clinical experience on cardiovascular imaging with revolution CT  
R. Schmitt; Bad Neustadt An Der Saale/DE  
4D CT imaging: from morphology towards functional assessment  
L. Macron; Saint Denis/FR  
Cardiac CT with isosmolar contrast media: higher comfort, better image?  
C. Loewe; Vienna/AT  
12:30 - 13:30 Room N 
Breast  
SY 25  
Early detection of breast cancer and dose 




Photon counting technology: early detection and dose reduction for 
mammography and tomosynthesis  
J. Rehn; Solna/SE  
With its high efficiency and low noise, photon counting technology can provide 
excellent image quality at a very low dose in mammography. The performance 
has been proven clinically; for instance in a recent study by Weigel et al., 
where photon-counting mammography had a significantly higher cancer 
detection rate compared to a comparable patient group screened with 
conventional technology. At the same time the dose was more than 60% lower. 
This is made possible by the photon-counting detectors in combination with a 
scanning geometry with multiple thin detector lines. This configuration provides 
intrinsic near-perfect scatter rejection and no additional grid is needed. This 
factor alone can reduce the dose by a third compared to conventional full-area 
detectors. Application of more than one energy threshold allows for true 
spectral imaging, where a low- and a high-energy image are acquired in a 
single shot. This way, additional information can be extracted and different 
tissue types can be separated. One application is measurement of the 
volumetric glandularity of the breast, which does not rely on an uncertain 
physical measurement of the compressed breast thickness. The photon-
counting technology and scanning geometry is easily adaptable to breast 
tomosynthesis. By changing the scanning motion, each detector line is imaging 
the breast from a different angle thus providing all tomographic projections in a 
single scan at the same time as for 2D mammography. The low noise, low 
dose and scatter removal features are preserved. Hence, excellent clinical 
performance can be expected for a photon-counting tomosynthesis system. In 
2012 Wallis et al reported that photon counting tomosynthesis outperforms 2D 
mammography for readers with the least experience with lower x-ray dose 
compared to conventional full-area detectors.  
Spectral lesion characterisation: initial clinical results  
N. Wieberneit; Hamburg/DE  
Between 2009 and 2013 we screened 68423 women over 50 and recalled 
2367 (3.5%). 485 (23%) of these women had solitary well-defined lesions, of 
which 267 were cysts (4 per 1,000 screens). These recalls cause stress to 
individuals and a cost to society. Techniques to improve characterisation at 
screening could reduce recalls. Having previously determined the spectrally 
resolved x-ray attenuation of cyst fluid and solid lesions on formalin fixed 
specimens, we aim to establish whether in-vivo solid and cystic lesions can be 
distinguished using spectral mammography in a pilot clinical study. All women 
undergoing mammograms as part of their routine diagnostic work-up were 
consented for analysis of spectral information obtained from regular imaging on 
a CE marked clinical mammography system (Philips MicroDose Spectral 
Imaging). Images were anonymized and analyzed retrospectively after 
diagnosis was confirmed with ultrasound and / or pathology. 144 solitary 
lesions (71 cysts and 73 solids) were delineated by an expert radiologist with 
elliptical contours for the lesion and a surrounding reference region. Based on 
the x-ray attenuation of cyst fluid and solid lesion specimens, a lesion 
characterisation algorithm modelling local breast height and composition was 
used to predict the cystic and solid volume fraction of the lesion, which is 
directly related to the probability of the lesion being cystic or solid. The lesion 
characterisation tool demonstrates promising results for determining the cystic 
vs solid nature of lesions on spectral mammography. Our results justify 
undertaking a larger reader study to refine the algorithm and determine 
clinically relevant thresholds to allow safe classification of cysts.  
Personalised breast care with a spectral breast density measurement  
B. Cederström; Solna/SE  
Photon counting spectral imaging provides high detective quantum efficiency, 
low dose and material decomposition with spectral breast density 
measurement as the first clinical application. Breast density is a risk factor for 
breast cancer and an indicator for the sensitivity of mammography. A breast 
density measurement could be a starting point for a personalized screening 
plan with for example tailored screening interval and choice of imaging 
modality. Dual energy imaging is today a reference for body composition 
measurements, non-contrast spectral mammography brings this technology to 
breast imaging with potential improvements in accuracy. We report on our 
experience with using the Photon counting spectral mammography system in 
our clinical practice and present data on dose reduction and performance 
indicators of the image quality and of the spectral breast density measurement.  
12:30 - 13:30 Studio 2015 
SY 26  
Widening the spectrum of CT  
Moderator:  
A. Vlassenbroek; Brussels/BE 
Imaging biomarkers in CT: from the idea, through research to clinical 
innovation 
A. Alberich-Bayarri; Valencia/ES 
CT modality has suffered a tremendous revolution in the last decade. The 
enormous progress made in fields such as IMR or spectral CT has opened a 
new window to the applications of CT. Despite of this evolution, the current 
added values of CT are mainly related to the adequate processing of all the 
data they generate. 3D methods and advanced post-processing software have 
been integrated in workstations and client-server infrastructures to provide 
quantitative measurements that aid in the diagnosis or the evaluation of 
treatment effectiveness in patients. However, imaging biomarkers 
standardisation is still a challenge with a need for consensus. Although 
important efforts are being done by scientific societies in the definition of the 
structured reporting architecture, the progresses in the field of quantitative 
imaging have not been accompanied by a change of paradigm in reports. 
Therefore, there is a need for the establishment of workflows for the 
development and implementation of structured reports for CT imaging 
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biomarkers. In order to implement a complete methodology for the 
quantification of a biological or physiological property, all the steps in the 
imaging biomarkers implementation workflow must be carefully addressed. The 
post-processing platforms and PACS existing nowadays allow for the 
extraction of some imaging biomarkers but lack in the adequate storage of all 
the information in databases for scientific exploitation. The integration of 
imaging biomarkers working in multidisciplinary teams of radiology and 
engineering taking into account all the steps of the workflow will have an 
enormous impact in the upcoming advances of CT. 
Iterative model reconstruction (IMR) in routine clinical use 
C. Yeong; Warrington/UK 
Indications for CT scans and frequency of repeat scans have been increasing. 
This has contributed to a significant increase in the exposure of radiation to the 
general population. Knowledge based iterative reconstruction promises to be a 
major significant leap forward in dose reduction. In Warrington, we have been 
scanning with IMR for the past 12 months. In CT brain, using IMR, we average 
CTDI = 20mGy, DLP = 400mGy cm. This is a reduction of 40 - 50% of the 
typical doses in most hospitals1. In CT of the thorax, the average in many dose 
surveys is CTDI of 11mGy. With IMR, the average CTDI is 3mGy. In High 
resolution lung scans (HRCT), the degree of dose reduction is less significant. 
In CT of the abdomen & pelvis, the low noise images allow much better density 
appreciation of soft tissue structures. Average UK doses are CTDI=13 mGy 
cm, DLP=700 mGy cm, with IMR, our average doses are CTDI=4 mGy cm, 
DLP=300 mGy cm. IMR is particularly useful for obese patients, as noise is 
very well suppressed. Enhancement of soft tissue structures with iodinated 
contrast is more easily appreciated. We routinely scan with 100kV for patients 
up to 85kg. This results in greater soft tissue enhancement post-contrast. With 
CT colon, our routine protocol is for an ultra -low dose prone scan followed by 
a low supine scan to view extra-colonic structures. With IMR, the total for both 
scans is DLP=170mGy (about 2.5 mSv). In CT angiography, the low noise 
images allow us to exploit the k-edge of iodine by using 80 kV in CT pulmonary 
angiography allowing lower contrast volume and flow rates to be used. Body 
angiography is performed with 100kV, in patients up to 130kg, with overall 
dose reduction of >60% 
Learning Objectives: 
1. To learn about the strengths of using IMR in various anatomical areas and 
different clinical scenarios are discussed. 
2. To learn about the disadvantages and limitations of IMR in daily practice, 
illustrating the degree of dose reduction versus image quality that is achieved 
in routine use. 
3. To become familiar with the routine use of IMR in a busy district hospital and 
whether there is any impact to work-flow. 
Innovations in routine spectral CT 
N.N. 
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